About Rodin

Therapeutic Strategy

Our early clinical and translational efforts are focused on confirming that our proprietary compounds are safe and brain penetrant, with appropriate pharmacokinetic properties. Critically, we also plan to leverage target engagement and pharmacodynamic biomarkers to confirm the sustained, significant increase in synaptic resilience shown preclinically with our compounds.

Rodin is currently focused on generating a proof of mechanistic principle – confirming that our compounds improve synaptic resilience in human brain, as they do in preclinical models – to enable multiple potential development pathways.